ACUMEN PHARMACEUTICALS

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

26 9 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

25 9 2024 13:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

03 9 2024 13:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights

13 8 2024 04:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

06 8 2024 13:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease

29 7 2024 04:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

28 7 2024 04:30:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

11 7 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

14 5 2024 04:00:01 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 5 2024 13:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

08 5 2024 14:47:25 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

08 5 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

07 5 2024 13:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

16 4 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

04 4 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

26 3 2024 04:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

21 3 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

19 3 2024 13:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

12 3 2024 13:00:00 提供 Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

08 3 2024 05:50:00 提供 Nasdaq GlobeNewswire